CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Axsome Therapeutics gained more than $1 billion in market value Monday, after the brain drug developer disclosed a patent ...

The Federal Trade Commission has opened an investigation into Teva Pharmaceuticals, citing the company’s refusal to take down ...

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.

The success of Epidiolex prompted several companies to attempt to create generic versions. Jazz Pharmaceuticals plc (NASDAQ: ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Teva Pharmaceuticals (TEVA) resolving all patent ...